The FDA has accepted a biologics license application for brolucizumab for the treatment of neovascular age-related macular degeneration, Novartis …



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *